FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334651034> ?p ?o ?g. }

• W2334651034 abstract "Synergistic cytotoxicity with high-dose statins and erlotinib has been demonstrated in preclinical models across a number of tumour types. In this phase I study, we evaluated the safety and potential anti-tumour activity of escalating doses of rosuvastatin in combination with the standard clinical dose of erlotinib in heavily pretreated patients with advanced solid tumours. This was a single-center, phase I open-label study to determine the safety and recommended phase two dose (RPTD) of rosuvastatin in combination with 150 mg/day standard dose of erlotinib. Using a 3 + 3 study design and 28-day cycle, escalating doses of rosuvastatin from 1 to 8 mg/kg/day ×2 weeks (cycle 1) and 3 weeks (subsequent cycles) given concurrently with erlotinib were evaluated. In order to expand the experience and to gain additional safety and pharmacokinetic data, two expansions cohorts using concurrent or alternating weekly dosing regimens at the RPTD were also evaluated. All 24 patients enrolled were evaluable for toxicity, and 22 for response. The dose-limiting toxicity (DLT) of reversible muscle toxicity was seen at the 2 mg/kg/day dose level. Maximal tolerated dose (MTD) was determined to be 1 mg/kg/day. Thirty-three percent of patients developed at least 1≥ grade 2 muscle toxicity (rhabdomyolysis: 1/24, myalgia: 7/24) resulting in one study-related death. Durable stable disease for more than 170 days was seen in 25 % of patients that received concurrent treatment and were evaluable for response (n = 16). Plasma erlotinib levels on study were unaffected by the addition of rosuvastatin. The observed disease stabilization rate of 25 % with combination therapy in this heavily pretreated population is encouraging, however, the high levels of muscle toxicities observed limited this combination strategy." @default.
• W2334651034 created "2016-06-24" @default.
• W2334651034 creator A5001083476 @default.
• W2334651034 creator A5009677422 @default.
• W2334651034 creator A5016140316 @default.
• W2334651034 creator A5018001559 @default.
• W2334651034 creator A5051505642 @default.
• W2334651034 creator A5061917666 @default.
• W2334651034 creator A5063860482 @default.
• W2334651034 creator A5077884585 @default.
• W2334651034 date "2016-03-31" @default.
• W2334651034 modified "2023-10-17" @default.
• W2334651034 title "A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies" @default.
• W2334651034 cites W153618619 @default.
• W2334651034 cites W1963958736 @default.
• W2334651034 cites W1965456668 @default.
• W2334651034 cites W1979556028 @default.
• W2334651034 cites W1985536810 @default.
• W2334651034 cites W1990063973 @default.
• W2334651034 cites W1999164183 @default.
• W2334651034 cites W2004362238 @default.
• W2334651034 cites W2008888925 @default.
• W2334651034 cites W2026834760 @default.
• W2334651034 cites W2042867060 @default.
• W2334651034 cites W2043696829 @default.
• W2334651034 cites W2045712888 @default.
• W2334651034 cites W2066135509 @default.
• W2334651034 cites W2071124826 @default.
• W2334651034 cites W2074141756 @default.
• W2334651034 cites W2079286299 @default.
• W2334651034 cites W2079430799 @default.
• W2334651034 cites W2081911594 @default.
• W2334651034 cites W2084800358 @default.
• W2334651034 cites W2096198395 @default.
• W2334651034 cites W2097254028 @default.
• W2334651034 cites W2103134643 @default.
• W2334651034 cites W2104192439 @default.
• W2334651034 cites W2110171695 @default.
• W2334651034 cites W2111662961 @default.
• W2334651034 cites W2112106048 @default.
• W2334651034 cites W2113341349 @default.
• W2334651034 cites W2117046467 @default.
• W2334651034 cites W2129360604 @default.
• W2334651034 cites W2130940092 @default.
• W2334651034 cites W2135836172 @default.
• W2334651034 cites W2137405846 @default.
• W2334651034 cites W2138297714 @default.
• W2334651034 cites W2139248078 @default.
• W2334651034 cites W2145376550 @default.
• W2334651034 cites W2156394877 @default.
• W2334651034 cites W2160982674 @default.
• W2334651034 cites W2161821474 @default.
• W2334651034 cites W2164884234 @default.
• W2334651034 cites W2167737594 @default.
• W2334651034 cites W4254030242 @default.
• W2334651034 doi "https://doi.org/10.1186/s12967-016-0836-6" @default.
• W2334651034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4815068" @default.
• W2334651034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27036206" @default.
• W2334651034 hasPublicationYear "2016" @default.
• W2334651034 type Work @default.
• W2334651034 sameAs 2334651034 @default.
• W2334651034 citedByCount "18" @default.
• W2334651034 countsByYear W23346510342017 @default.
• W2334651034 countsByYear W23346510342018 @default.
• W2334651034 countsByYear W23346510342019 @default.
• W2334651034 countsByYear W23346510342020 @default.
• W2334651034 countsByYear W23346510342021 @default.
• W2334651034 countsByYear W23346510342022 @default.
• W2334651034 countsByYear W23346510342023 @default.
• W2334651034 crossrefType "journal-article" @default.
• W2334651034 hasAuthorship W2334651034A5001083476 @default.
• W2334651034 hasAuthorship W2334651034A5009677422 @default.
• W2334651034 hasAuthorship W2334651034A5016140316 @default.
• W2334651034 hasAuthorship W2334651034A5018001559 @default.
• W2334651034 hasAuthorship W2334651034A5051505642 @default.
• W2334651034 hasAuthorship W2334651034A5061917666 @default.
• W2334651034 hasAuthorship W2334651034A5063860482 @default.
• W2334651034 hasAuthorship W2334651034A5077884585 @default.
• W2334651034 hasBestOaLocation W23346510341 @default.
• W2334651034 hasConcept C112705442 @default.
• W2334651034 hasConcept C121608353 @default.
• W2334651034 hasConcept C126322002 @default.
• W2334651034 hasConcept C143998085 @default.
• W2334651034 hasConcept C2777288759 @default.
• W2334651034 hasConcept C2777334693 @default.
• W2334651034 hasConcept C2778087573 @default.
• W2334651034 hasConcept C2779438470 @default.
• W2334651034 hasConcept C2780499067 @default.
• W2334651034 hasConcept C2908737378 @default.
• W2334651034 hasConcept C29730261 @default.
• W2334651034 hasConcept C71924100 @default.
• W2334651034 hasConcept C98274493 @default.
• W2334651034 hasConceptScore W2334651034C112705442 @default.
• W2334651034 hasConceptScore W2334651034C121608353 @default.
• W2334651034 hasConceptScore W2334651034C126322002 @default.
• W2334651034 hasConceptScore W2334651034C143998085 @default.
• W2334651034 hasConceptScore W2334651034C2777288759 @default.
• W2334651034 hasConceptScore W2334651034C2777334693 @default.
• W2334651034 hasConceptScore W2334651034C2778087573 @default.
• W2334651034 hasConceptScore W2334651034C2779438470 @default.

• next